

CareCloud Reports Record Full Year 2022 Results

SOMERSET, N.J., March 2, 2023 (GLOBE NEWSWIRE) – <u>CareCloud, Inc.</u> (the "Company" or "CareCloud") (Nasdaq: CCLD, CCLDP and CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced financial and operational results for the year ended December 31, 2022. The Company's management will conduct a conference call with related slides today at 8:30 a.m. Eastern Time to discuss these results and management's outlook for the year.

"2022 was a successful transformational year for CareCloud," said A. Hadi Chaudhry, CareCloud's Chief Executive Officer and President. "We launched several new products, including CareCloud Remote for home healthcare and CareCloud Wellness, which expanded our digital health portfolio to provide chronic care management and remote patient monitoring to a rapidly growing user base. The combination of broadening our service offering with these new products and successful focus on organic growth were primary drivers that helped us achieve record bookings in 2022, which is more than double the previous year. We are on a mission to redefine technology-enabled revenue cycle solutions for healthcare and are positioned well to build on this momentum in 2023."

Full Year 2022 Highlights

- Revenue of \$138.8 million, as compared to \$139.6 million in 2021
- Record GAAP net income of \$5.4 million, compared to \$2.8 million in 2021
- Adjusted net income of \$16.3 million or \$1.07 per share, compared to \$18.5 million or \$1.24 per share in 2021
- Record adjusted EBITDA of \$22.2 million, an increase of \$129,000 over \$22.1 million in 2021

Fourth Quarter 2022 Highlights

- Revenue of \$32.5 million, as compared to \$37.5 million in Q4 2021
- GAAP net income of \$499,000, compared to \$3.5 million in Q4 2021
- Adjusted net income of \$3.9 million, or \$0.25 per share
- Adjusted EBITDA of \$5.7 million, as compared to \$6.1 million in Q4 2021

Full Year 2022 Financial Results

Revenue for 2022 was \$138.8 million, a 1% decline compared to \$139.6 million in 2021.

Bill Korn, CareCloud's Chief Financial Officer remarked, "when we acquired Meridian Medical Management in mid-2020, their two largest clients were health systems which had each been acquired in 2016 and 2018, and were in the process of migrating away from Meridian onto the platforms utilized by their acquirers. We recognized that we could not stop this migration, for which significant money had already been expended, and understood that we would eventually lose this revenue, though we didn't know how long the migrations would actually take. Both clients finished the majority of their migrations in mid-2022. Our 2021 revenue of \$139.6 million would have been

\$118.1 million excluding these clients, and our 2022 revenue without these clients was \$126.7 million. So, excluding these clients from both years, we would have recorded revenue growth of 7% in 2022."

"Approximately 88% of our 2022 revenue came from technology-enabled business solutions. Clients using our technology-enabled revenue cycle management services represented approximately 52% of our revenue, with over 90% of that revenue coming from clients who also utilized our EHR or practices management software as well as our services. Approximately 12% of our revenue came from clients utilizing our cloud-based software without a services component, and 24% of our revenue came from professional services, such as our medSR professional services geared towards hospitals and large health systems and CareCloud FORCE workforce augmentation. All of these revenue streams leverage the power of our technology and our low-cost, world-class team."

"Approximately 10% of our revenue was from clients where we are managing their entire medical practice, and approximately 2% of revenue came from other services."

CareCloud's GAAP net income was \$5.4 million, compared to \$2.8 million in 2021. This is CareCloud's second consecutive year of positive GAAP net income since its IPO in 2014, representing approximately 92% growth year-over-year. GAAP net loss per share was \$0.67, based on the net loss attributable to common shareholders, which takes into account the preferred stock dividends declared during the year.

Non-GAAP adjusted net income for 2022 was \$16.3 million or \$1.07 per share. Non-GAAP adjusted net income excludes non-cash expenses such as depreciation and amortization as well as the gain from the change in contingent consideration.

Adjusted EBITDA was \$22.2 million, an increase of \$129,000 from \$22.1 million last year, despite the loss of revenue from the two large clients which were acquired and who were previously very profitable, and despite increasing our sales and marketing spending by approximately \$1 million.

Fourth Quarter 2022 Financial Results

Revenue for the fourth quarter 2022 was \$32.5 million, a decrease of 13% from the fourth quarter of 2021, primarily due to the decrease from the two large clients previously mentioned.

Fourth quarter 2022 GAAP net income was \$499,000, compared to \$3.5 million in the same period last year. "While the management team looks at adjusted EBITDA and cash flow from operations as the primary indicators of whether our business is growing in a sustainable way, achieving positive GAAP profitability for six consecutive quarters is a great indication of our progress," remarked Bill Korn. GAAP net loss per share for fourth quarter 2022 was \$0.22, based on the net income attributable to common shareholders.

Non-GAAP adjusted net income for fourth quarter 2022 was \$3.9 million, or \$0.25 per share, and is calculated using the end-of-period common shares outstanding. Non-GAAP adjusted net income exceeded the quarterly dividend paid to preferred shareholders.

Adjusted EBITDA for fourth quarter 2022 was \$5.7 million, or 17% of revenue, compared to \$6.1 million in the same period last year.

Cash Balances and Capital Structure

As of December 31, 2022, the Company had approximately \$12.3 million of cash. During the fourth quarter 2022, cash flow from operations was approximately \$6.0 million. Our net working capital on December 31, 2022 was approximately \$12.3 million.

On December 31, 2022, the Company had 4,526,231 shares of non-convertible Series A Preferred Stock outstanding, and 1,344,128 shares of non-convertible Series B Preferred Stock outstanding. The Series A shares pay cash dividends at the rate of 11% per annum of the \$25.00 per share liquidation preference (equivalent to \$2.75 annually per share), but they are fully redeemable at the Company's option at \$25.00 per share. During 2022, the Company sold approximately 1.3 million shares of non-convertible Series B Preferred Stock, which is similar to Series A Preferred Stock, but with an 8.75% annual cash dividend. The Company used \$20 million of the proceeds from the Series B offering to redeem 800,000 shares of Series A Preferred Stock on March 18, 2022. Series B shares are redeemable at the Company's option beginning in February 2024.

2023 Guidance

CareCloud is providing the following forward-looking guidance for the fiscal year ending December 31, 2023:

For the Fiscal Year Ending December 31, 2023 Forward-Looking Guidance								
Revenue \$142 – \$146 million								
Adjusted EBITDA	\$24 – \$27 million							

The Company anticipates full year 2023 revenue of approximately \$142 to \$146 million. Revenue guidance is based on management's expectations regarding revenues from existing clients, including adoption of CareCloud Wellness which was introduced in 2022, as well as new clients acquired through organic growth. We have excluded the effects of any future acquisitions or tuckins, and made assumptions about the timing for new customers going live and the adoption rates of new services. This implies 12% net organic growth from 2022 to 2023, excluding the revenue from the two large clients who were previously acquired and migrated off our services in mid-2022.

Adjusted EBITDA is expected to be \$24 to \$27 million for full year 2023, which implies growth of approximately 15% from 2022 to 2023, without the effects of any future acquisitions or tuck-ins.

Conference Call Information

CareCloud management will host a conference call today at 8:30 a.m. Eastern Time to discuss the full year 2022 results. The live webcast of the conference call **and related presentation slides** can be accessed under Events & Presentations at <u>ir.carecloud.com/events/</u>. An audio-only option is available by dialing 201-389-0920 and referencing "CareCloud Fourth Quarter 2022 Earnings Call." Investors who opt for audio only will need to download the related slides at <u>ir.carecloud.com/events/</u>.

A replay of the conference call with slides will be available approximately one hour after conclusion of the call at the same <u>link</u>. An audio replay can also be accessed by dialing 412-317-6671 and providing access code 13736125.

About CareCloud

CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health at www.carecloud.com.

Follow CareCloud on LinkedIn, Twitter and Facebook.

For additional information, please visit our website at www.carecloud.com. To view CareCloud's latest investor presentations, read recent press releases, and listen to interviews with management, please visit ir-carecloud.com.

Use of Non-GAAP Financial Measures

In our earnings releases, prepared remarks, conference calls, slide presentations, and webcasts, we use and discuss non-GAAP financial measures, as defined by SEC Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. Our earnings press releases containing such non-GAAP reconciliations can be found in the Investor Relations section of our web site at ir.carecloud.com.

Forward-Looking Statements

This press release contains various forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "shall," "should," "could," "intends," "expects," "plans," "goals," "projects," "anticipates," "believes," "seek," "estimates," "forecast," "predicts," "possible," "potential," "target," or "continue" or the negative of these terms or other comparable terminology.

Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, statements reflecting management's expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, the impact of the Covid-19 pandemic on our financial performance and business activities, and the expected results from the integration of our acquisitions.

These forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry's) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to the Company's ability to manage growth, migrate newly acquired customers and retain new and existing customers, maintain cost-effective global operations, increase operational efficiency and reduce operating costs, predict and properly adjust to changes in reimbursement and other industry regulations and trends, retain the services of key personnel, develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards, compete with other companies products and services competitive with ours, and other important risks and uncertainties referenced and discussed under the heading titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission. In addition, there is uncertainty about the spread of the Covid-19 virus and the impact it may have on the Company's operations, the demand for the Company's services, and economic activity in general.

The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE CareCloud

Company Contact:

Bill Korn
Chief Financial Officer
CareCloud, Inc.
bkorn@carecloud.com

Investor Contact:

Asher Dewhurst ICR Westwicke CareCloudIR@westwicke.com

CARECLOUD, INC. CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2022 AND 2021

(\$ in thousands, except share and per share amounts)

Current assets: \$ 12,299 \$ 9,340 Cash \$ 12,299 \$ 9,340 Restricted cash - 1,000 Accounts receivable - net 11,773 17,006 Contract asset 4,399 4,725 Inventory 381 503 Current assets - related party 16 13 Total current assets 2,785 2,972 Total current assets 34,653 35,559 Property and equipment - net 5,056 5,040 Operating lease right-of-use assets 4,921 6,940 Intangible assets - net 29,520 30,778 Goodwill 61,186 61,186 Other assets 3136,174 \$ 140,848 LIABILITIES AND SHAREHOLDERS' EQUITY S 136,184 \$ 1,861 Current liabilities: 4,242 4,251 \$ 5,948 A ccounts payable \$ 5,681 \$ 5,948 A ccounts payable \$ 5,681 \$ 5,948 A ccounts payable \$ 2,273 3,963 9 5,948 A ccount oppopulation (current portion) \$ 2,27		Dec	ember 31, 2022	Dec	ember 31, 2021
Cash \$ 12,299 \$ 9,340 Restricted cash 1,000 Accounts receivable - net 14,773 1,000 Contract asset 14,773 17,006 Current assets 3,355 50 Current assets 2,725 2,972 Total current assets 34,653 35,559 Property and equipment - net 5,056 4,942 6,940 Operating lease right-of-use assets 4,921 6,940 Other assets 38,8 981 Order assets 38,8 981 Other assets 38,8 981 Other assets 38,8 981 LABLITIES AND SHAREHOLDERS'EQUITY Current liabilities 4,248 4,241 Accounts payable 5,681 5,948 4,241 Accured compensation 4,248 4,251 4,241 4,241 Accured compensation 4,248 4,251 4,241 4,251 4,241 4,251 4,251 4,241 4,251 4,241 4,251 4,251	ASSETS				
Restricted cash	Current assets:				
Accounts receivable - net	Cash	\$	12,299	\$	9,340
Contract asset 4,399 4,725 Inwentory 381 503 Current assets - related party 16 13 Prepaid expenses and other current assets 2,785 2,975 Total current assets 3,4653 35,559 Property and equipment - net 5,066 5,040 Operating lease right-of-use assets 29,520 30,778 Goodwill 61,186 61,186 Other assets 838 931 TOTAL ASSETS \$136,174 \$140,84 LABALITIES AND SHAREHOLDERS' EQUITY *** *** Current liabilities: *** *** *** Accrued compensation 4,432 5,091 *** Accrued expenses 4,432 5,091 *** Accrued expenses 4,432 5,091 *** Operating lease liability (current portion) 2,13 5,098 *** Notes payable (current portion) 1,36 1,095 *** Operating lease liability (current portion) 2,1 5,00 *** </td <td>Restricted cash</td> <td></td> <td>-</td> <td></td> <td>1,000</td>	Restricted cash		-		1,000
Inventory	Accounts receivable - net		14,773		17,006
Current assets - related party 16 13 Prepaid expenses and other current assets 2,785 2,972 Total current assets 34,653 35,559 Property and equipment - net 5,056 5,040 Operating lease right-of-use assets 29,202 30,778 Goodwill 61,186 6,186 Other assets 838 981 TOTAL ASSETS \$136,174 \$140,848 LABLITITES AND SHAREHOLDERS' EQUITY Turrent liabilities ** Current compensation 4248 \$5,948 Accrued expenses 4,432 5,091 Accrued expenses 4,432 5,091 Operating lease liability (current portion) 2,273 3,093 Deferred revenue (current portion) 3,273 3,903 Deferred payroll taxes - 3,994 Consideration (current portion) 313 3,44 Consideration payable 4,51 3,00 Consideration payable 5,00 3,00 Total current liabilities 3,20 4,545 <td>Contract asset</td> <td></td> <td>4,399</td> <td></td> <td>4,725</td>	Contract asset		4,399		4,725
Prepaid expenses and other current assets 2,785 2,975 Total current assets 34,553 35,559 Property and equipment - net 5,064 6,940 Operating lease right-of-use assets 4,921 6,940 Goodwill 61,186 61,186 61,186 Other assets 838 981 TOTAL ASSETS 136,174 140,848 LABILITIES AND SHAREHOLDERS' EQUITY Very Current liabilities: Accounts payable 5,5681 5,948 Accrued compensation 4,248 4,251 Accrued expenses 4,428 4,251 Operating lease liability (current portion) 2,273 3,963 Deferred revenue (current portion) 318 4,248 Deferred payroll taxes - 934 Notes payable (current portion) - 3,900 Deferred payroll taxes - 93 Notes payable (current portion) - 3,000 Consideration (wurrent portion) - 4,059 Deferred revenue (current portion) - 3,	,		381		503
Total current assets 34,653 35,559 Property and equipment - net 5,066 5,040 Operating lease right-of-use assets 4,921 6,940 Intangible assets - net 29,500 30,778 Goodwill 61,186 61,186 Other assets 838 981 TOTAL ASSETS \$136,174 \$140,848 LABRLITIES AND SHAREHOLDERS' EQUITY Current liabilities: \$5,681 \$5,948 Accrued compensation 4,248 4,251 5,948 Accrued expenses 4,248 4,251 5,091 Operating lease liability (current portion) 2,273 3,963 Deferred revenue (current portion) 1,386 1,085 Deferred payroll taxes - 934 Notes payable (current portion) 319 344 Consideration (current portion) 319 344 Consideration payable 4,029 3,856 Consideration payable 4,029 3,856 Consideration payable 3,000 3,000 Deferred tax lia			16		
Property and equipment - net	Prepaid expenses and other current assets		2,785		2,972
Operating lease right-of-use assets 4,921 6,940 Intangible assets - net 29,520 30,778 Goodwill 61,186 61,186 Other assets 8.38 981 TOTAL ASSETS \$136,174 \$140,848 LLABILITIES AND SHAREHOLDERS' EQUITY Current liabilities:	Total current assets		34,653		35,559
Intangible assets - net 29,520 30,778 Goodwill 61,186 61,186 Other assets 838 981 TOTAL ASSETS \$136,174 \$140,848 LABILITIES AND SHAREHOLDERS' EQUITY TURING AND SHAREHOLDERS' EQUITY TURING AND SHAREHOLDERS' EQUITY Corned compensation 4,248 5,5681 5,948 Accrued compensation 4,248 4,251 Accrued expenses 4,432 5,091 Operating lease liability (current portion) 1,386 1,085 Deferred revenue (current portion) 1,386 1,085 Deferred payroll taxes - 3,940 Notes payable (current portion) - 3,900 Consideration payable - 3,090 Consideration payable - 1,000 Total current liabilities 22,398 29,562 Notes payable 13 20 Borrowings under line of credit 8,000 8,000 Operating lease liability 3,20 4,545 TOMITIMENTS AND CONTINGENCIES 34,25	Property and equipment - net		5,056		5,404
Godwill 61,186 61,186 Other assets 838 981 LOTGAL ASSETS \$136,174 \$140,848 LABILITIES AND SHAREHOLDERS' EQUITY Secounts payable \$5,681 \$5,948 Accrued compensation 4,248 4,251 Accrued expenses 4,428 5,094 Accrued compensation 4,428 5,094 Accrued expenses 4,428 5,094 Operating lease liability (current portion) 2,273 3,963 Deferred revenue (current portion) 319 3,44 Notes payable (current portion) 319 3,44 Contingent consideration (current portion) 319 3,44 Consideration payable 4,059 3,856 Consideration payable 4,059 3,856 Consideration payable (current portion) 3,200 1,000 Total current liabilities 22,398 29,562 Notes payable (surent portion) 3,207 4,545 Borrowings under line of credit 3,000 3,000 Borrowings under line of credit	Operating lease right-of-use assets		4,921		6,940
Other assets 838 981 TOTAL ASSETS \$ 136,174 \$ 140,848 LABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounds payable \$ 5,681 \$ 5,948 Accound compensation 4,434 4,251 Accound expenses 4,432 5,091 Operating lease liability (current portion) 1,386 1,085 Deferred revenue (current portion) 1,386 1,085 Deferred payroll taxes - 934 Notes payable (current portion) - 3,940 Notes payable (current portion) - 1,000 Dividend payable 4,059 3,856 Consideration payable - 1,000 Total current liabilities 22,398 29,562 Notes payable (current portion) 3,207 4,545 Notes payable (payable 4,059 3,856 Consideration payable 3,207 4,545 Solve payable 3,300 8,000 Operating lease liability 3,207 4,545 Defe			29,520		30,778
TOTAL ASSETS \$ 140,848 LIABILITIES AND SHAREHOLDERS' EQUITY	Goodwill		61,186		61,186
Current liabilities	Other assets		838		981
Current liabilities: 5,681 5,948 Accoud compensation 4,248 4,251 Accrued expenses 4,432 5,091 Operating lease liability (current portion) 2,273 3,963 Deferred revenue (current portion) 1,386 1,085 Deferred payroll taxes - 934 Notes payable (current portion) - 3,090 Dividend payable 4,059 3,886 Consideration (current portion) - 3,090 Dividend payable 4,059 3,886 Consideration payable - 1,000 Total current liabilities 22,398 29,562 Notes payable (current portion) 13 20 Borrowings under line of credit 8,000 3,806 Consideration payable 13 20 Borrowings under line of credit 8,000 8,000 Operating lease liability 3,207 4,545 Deferred revenue 342 341 Deferred tax liabilities 34,485 42,917 COM	TOTAL ASSETS	\$	136,174	\$	140,848
Accounts payable \$ 5,681 \$ 5,948 Accrued compensation 4,248 4,251 Accrued expenses 4,432 5,091 Operating lease liability (current portion) 2,273 3,963 Deferred revenue (current portion) 1,386 1,085 Deferred payroll taxes - 934 Notes payable (current portion) 319 344 Contingent consideration (current portion) - 3,090 Dividend payable - 1,000 Consideration payable - 1,000 Consideration payable - 1,000 Borrowings under line of credit 8,000 8,000 Borrowings under line of credit 8,000 8,000 Borrowings under line of credit 3,207 4,545 Deferred revenue 342 341 Deferred tax liabilities 34,485 42,917 COMMITMENTS AND CONTINGENCIES 34,485 42,917 SHAREHOLDERS' EQUITY: Preferred stock, 50,001 par value - authorized 7,000,000 shares. Issued 15,970,204 and 5 Series B,	LIABILITIES AND SHAREHOLDERS' EQUITY				
Accrued compensation 4,248 4,251 Accrued expenses 4,432 5,091 Operating lease liability (current portion) 2,273 3,963 Deferred revenue (current portion) 1,1366 1,085 Deferred payroll taxes - 934 Notes payable (current portion) 319 344 Contingent consideration (current portion) - 3,090 Dividend payable 4,059 3,856 Consideration payable - 1,000 Total current liabilities 2,2398 29,562 Notes payable 5 13 20 Borrowings under line of credit 8,000 8,000 Operating lease liability 8,000 8,000 Operating lease liability 3,207 4,545 Deferred revenue 3,327 4,545 Deferred revenue 3,327 4,545 Deferred tax liabilities 3,441 Deferred tax liabilities 3,445 Total liabilities 34,485 42,917 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, \$0,001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2021, respectively. Additional paid-in capital 1,344,128 shares at December 31, 2021, respectively. Accumulated deficit (25,621) (31,053) Accumulated officit (25,621) (31,053)	Current liabilities:				
Accrued expenses 4,432 5,091 Operating lease liability (current portion) 2,273 3,663 Deferred revenue (current portion) 1,386 1,085 Deferred payroll taxes - 934 Notes payable (current portion) - 3,090 Dividend payable 4,059 3,856 Consideration payable - 1,000 Total current liabilities 22,398 29,562 Notes payable 13 20 Borrowings under line of credit 8,000 8,000 Operating lease liability 3,207 4,545 Deferred revenue 342 341 Deferred tax liabilities 34,485 42,917 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. 6 5 Series B, issued and outstanding 1,344,128 shares at December 31, 2021, respectively. 6 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares a	Accounts payable	\$	5,681	\$	5,948
Operating lease liability (current portion) 2,273 3,963 Deferred revenue (current portion) 1,386 1,085 Deferred payroll taxes - 934 Notes payable (current portion) 319 344 Contingent consideration (current portion) - 3,090 Dividend payable 4,059 3,856 Consideration payable - 1,000 Total current liabilities 22,398 29,562 Notes payable 13 20 Borrowings under line of credit 8,000 8,000 Operating lease liability 3,207 4,545 Deferred revenue 342 341 Deferred tax liability 3207 4,545 Comminity MENTS AND CONTINGENCIES 34,485 42,917 SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. 6 5 Series B, issued and outstanding 1,344,128 shares at December 31, 2021, respectively. 6 5 Common stock, \$0.001 par value - authorized 35,000,0	Accrued compensation		4,248		4,251
Deferred revenue (current portion) 1,386 1,085 Deferred payroll taxes - 934 Notes payable (current portion) - 3,090 Dividend payable 4,059 3,856 Consideration payable - 1,000 Total current liabilities 22,398 29,562 Notes payable 13 20 Borrowings under line of credit 8,000 8,000 Operating lease liability 3,207 4,545 Deferred revenue 342 341 Deferred tax liabilities 34,485 42,917 COMMITMENTS AND CONTINGENCIES 34,485 42,917 SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. 6 5 Series B, issued and outstanding 1,344,128 shares at December 31, 2021, respectively. 6 5 Series B, issued and outstanding 1,344,128 shares at December 31, 2021, respectively. 6 5 Series B, issued and outstanding 1,344,128 shares at December 31, 2021, respectively. 6 5	Accrued expenses		4,432		5,091
Deferred payroll taxes	Operating lease liability (current portion)		2,273		3,963
Notes payable (current portion) 319 344 Contingent consideration (current portion) - 3,990 Dividend payable 4,059 3,856 Consideration payable - 1,000 Total current liabilities 22,398 29,562 Notes payable 13 20 Borrowings under line of credit 8,000 8,000 Operating lease liability 3,207 4,545 Deferred revenue 342 341 Deferred tax liabilities 34,485 42,917 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, \$0,001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. 6 5 Common stock, \$0,001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 5 5 Common stock, \$0,001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 16 5 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (30,37)	Deferred revenue (current portion)		1,386		1,085
Contingent consideration (current portion) - 3,090 Dividend payable 4,059 3,856 Consideration payable - 1,000 Total current liabilities 22,398 29,562 Notes payable 13 20 Borrowings under line of credit 8,000 8,000 Operating lease liability 3,207 4,545 Deferred revenue 34,2 341 Deferred tax liability 525 449 Total liabilities 34,85 42,917 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. 6 5 Series B, issued and outstanding 1,344,128 shares at December 31, 2022. 6 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2021, respectively. 16 16 Additional paid-in capital 130,987 131,379	Deferred payroll taxes		-		934
Dividend payable 4,059 3,856 Consideration payable - 1,000 Total current liabilities 22,398 29,562 Notes payable 13 20 Borrowings under line of credit 8,000 8,000 Operating lease liability 3,207 4,545 Deferred revenue 342 341 Deferred tax liabilities 34,855 42,917 COMMITMENTS AND CONTINGENCIES S SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2022, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2021, respectively. 15,627,641 shares at December 31, 2022 and December 31, 2021, respectively. 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively. 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (3),03	Notes payable (current portion)		319		344
Consideration payable - 1,000 Total current liabilities 22,398 29,562 Notes payable 13 20 Borrowings under line of credit 8,000 8,000 Operating lease liability 3,207 4,545 Deferred revenue 342 341 Deferred tax liability 525 449 Total liabilities 34,485 42,917 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. 6 5 Series B, issued and outstanding 1,344,128 shares at December 31, 2022, respectively. 6 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. 16 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively. 16 16 Accumulated deficit (3,037)	Contingent consideration (current portion)		-		3,090
Total current liabilities	• •		4,059		3,856
Notes payable 13 20 Borrowings under line of credit 8,000 8,000 Operating lease liability 3,207 4,545 Deferred revenue 342 341 Deferred tax liability 525 449 Total liabilities 34,485 42,917 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2022. 6 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,625,461 shares at December 31, 2022 and December 31, 2021, respectively. 16 16 Additional paid-in capital 16 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, 2022	Consideration payable				1,000
Borrowings under line of credit 8,000 8,000 Operating lease liability 3,207 4,545 Deferred revenue 342 341 Deferred tax liability 525 449 Total liabilities 34,485 42,917 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. 6 5 Series B, issued and outstanding 1,344,128 shares at December 31, 2022, respectively. 6 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Outstanding 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively. 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31,	Total current liabilities		22,398		29,562
Operating lease liability 3,207 4,545 Deferred revenue 342 341 Deferred tax liability 525 449 Total liabilities 34,485 42,917 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2022 6 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Outstanding 15,229,405 and 14,916,842 shares at December 31, 2021, respectively. Outstanding 16,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and 20, 20, 20, 20, 20, 20, 20, 20, 20			13		20
Deferred revenue 342 341 Deferred tax liability 525 449 Total liabilities 34,485 42,917 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2022 6 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Outstanding 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, 2022 and December 31, 2022 and December 31, 2023 and December 31, 2024 and December 31, 2025 and Decemb			8,000		8,000
Deferred tax liability	Operating lease liability		3,207		4,545
Total liabilities 34,485 42,917 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2022 66 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Outstanding 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively 16 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, 2022 and December 31, 2021 (662) (662) Total shareholders' equity 101,689 97,931	Deferred revenue		342		341
COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2022 6 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Outstanding 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, 2022 and December 31, 2021 (662) (662) Total shareholders' equity 101,689 97,931	Deferred tax liability		525		449
SHAREHOLDERS' EQUITY: Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2022 6 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Outstanding 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, 2022 and December 31, 2021 (662) (662) Total shareholders' equity 101,689 97,931			34,485		42,917
Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2022 6 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Outstanding 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, 2022 and December 31, 2021 and December 31, 2021 and December 31, 2021 and December 31, 2022 and December 31, 2021 and December 31, 2021 and December 31, 2021 and December 31, 2022 and December 31, 2021 and December 31, 2021 and December 31, 2022 and December 31, 2021 and December 31, 2022 and December 31, 2021 an	COMMITMENTS AND CONTINGENCIES				
4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2022 6 5 Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Outstanding 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, 2022 and December 31, 2021 Total shareholders' equity 101,689 97,931	SHAREHOLDERS' EQUITY:				
Common stock, \$0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Outstanding 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, (662) (662) Total shareholders' equity 101,689 97,931	Preferred stock, \$0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively.				_
15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Outstanding 16 16 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively 16 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, (662) (662) Total shareholders' equity 101,689 97,931			6		5
15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively 16 16 Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, (662) (662) Total shareholders' equity 101,689 97,931	-				
Additional paid-in capital 130,987 131,379 Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, (662) (662) Total shareholders' equity 101,689 97,931			16		10
Accumulated deficit (25,621) (31,053) Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, (662) (662) Total shareholders' equity 101,689 97,931	-				
Accumulated other comprehensive loss (3,037) (1,754) Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, 2021 (662) (662) Total shareholders' equity 101,689 97,931					
Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, (662) (662) 2021 101,689 97,931					
2021 (662) (662) Total shareholders' equity 101,689 97,931	·		(3,037)		(1,754)
Total shareholders' equity 101,689 97,931			(662)		(662)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY \$\frac{136,174}{2}\$\$\frac{140,848}{2}\$					
	TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$	136,174	2	140,848

CARECLOUD, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2022 AND 2021

(\$ in thousands, except share and per share amounts)

		Three Mor	ıths	Ended		Year I	nde	d	
	December 31,					Decemb	ber 3	31,	
		2022		<u>2021</u>		2022		2021	
NET REVENUE	\$	32,534	\$	37,462	\$	138,826	\$	139,599	
OPERATING EXPENSES:									
Direct operating costs		19,568		24,200		84,434		86,918	
Selling and marketing		2,474		2,317		9,788		8,786	
General and administrative		5,341		6,459		23,820		24,273	
Research and development		1,150		81		4,401		4,408	
Change in contingent consideration		(200)		(2,515)		(3,090)		(2,515)	
Depreciation and amortization		3,039		2,689		11,725		12,195	
Net loss on lease termination, impairment and unoccupied lease charges	_	210		340		1,138		2,005	
Total operating expenses	_	31,582		33,571		132,216		136,070	
OPERATING INCOME		952		3,891		6,610		3,529	
OTHER:									
Interest income		19		5		41		15	
Interest expense		(102)		(181)		(405)		(455)	
Other expense - net	_	(337)		(16)		(637)		(96)	
INCOME BEFORE PROVISION FOR INCOME TAXES		532		3,699		5,609		2,993	
Income tax provision		33		177		177		157	
NET INCOME	<u>s</u>	499	\$	3,522	\$	5,432	\$	2,836	
Preferred stock dividend		3,855		3,644		15,517		14,052	
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	\$	(3,356)	\$	(122)	S	(10,085)	\$	(11,216)	
Net loss per common share: basic and diluted	S	(0.22)	\$	(0.01)	S	(0.67)	\$	(0.77)	
Weighted-average common shares used to compute basic and diluted loss per share		15,224,347		14,900,391		15,109,587		14,541,061	

CARECLOUD, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021

(\$ in thousands)

Net income Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 12,318 12,676 Lease amortization 3,286 3,574 Deferred revenue 302 (72) Provision for doubfful accounts 740 899 Provision for debefred income taxes 56 289 Foreign exchange loss (gain) 610 610 610 Interest accretion 596 857 Loss on sale of assets 610 3,909 (2,515) Interest accretion 630 (3,090) (2,515) Adjustment of goodwill 640 3,909 (2,515) Adjustment of goodwill 650 620 620 620 620 620 620 620 620 620 62	ODED ATING ACTIVITIES.		2022		<u>2021</u>
Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization	OPERATING ACTIVITIES:	Φ.	£ 422	Φ.	2 926
Depreciation and amortization		Ф	3,432	Φ	2,030
Lease amortization 3,286 3,574 Deferred evenue 302 (72) Provision for doubtful accounts 740 890 Provision for doubtful accounts 760 289 Provision for deferred income taxes 76 289 Provision for deferred income taxes 76 289 Provision for deferred income taxes 76 289 Foreign exchange loss (gain) 610 (160 161 1			12.318		12 676
Deferred revenue 302 772 Provision for doubtful accounts 740 890 Provision for deferred income taxes 76 289 Foreign exchange loss (gain) 610 (16) Interest accretion 596 857 Loss on sale of assets - 172 Stock-based compensation expense 4,914 5,396 Change in contingent consideration 3,090 (2,515) Adjustment of goodwill - 360 Change in poerating assets and liabilities, net of businesses acquired: 1,493 6(20) Contract asset 326 6(200) Inventory 122 (104) Other assets 619 921 Accounts receivable 6,593 (10,366) Net cash provided by operating activities (6,593) (10,366) Net cash provided by operating activities (6,593) (10,366) Net cash provided by operating activities (1,767) (2,158) NUESTING ACTIVITIES: Purchases of property and equipment (2,588) (2,928) Capitalized software (9,179) (7,636) Cash paid for acquisition (net) - 1 (12,582) Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: Preferred stock dividends paid (15,314) (14,437) Settlement of contingent obligation (1,000) Settlement of contingent obligation (1,000) Settlement of contingent obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from issuance of Series B Preferred Stock, net of expenses - 2,731 Redemption of Series A Preferred Stock (20,005) Proceeds from issuance of Series B Preferred Stock, net of expenses - 2,731 Redemption of Series A Preferred Stock (20,005) Proceeds from issuance of Series B Preferred Stock, net of expenses - 2,731 Redemption of Series A Preferred Stock (20,005) Proceeds from issuance of series B Preferred Stock (20,005) Proceeds from issuance of series B Preferred Stock (20,005) Proceeds from issuance of series B Preferred Stock (20,005					-
Provision for doubtful accounts 740 890 Provision for deferred income taxes 76 289 Foreign exchange loss (gain) 610 (16) Loss on sale of assets - 172 Stock-based compensation expense 4,914 5,396 Change in contingent consideration (3,090) (2,515) Adjustment of goodwill - 36 Changes in operating assets and liabilities, net of businesses acquired: 1,493 (620) Contract asset 326 (620) Other assets 619 921 Accounts payable and other liabilities (6,593) (10,366) Net cash provided by operating activities 21,151 13,334 Investing ACTIVITIES: Purchases of property and equipment (2,588) (2,928) Capitalized software (9,179) (7,636) (23,149) FINANCING ACTIVITIES: 11,767 (23,149) Pricered stock dividends paid (1,167) (23,149) Settlement of contingent obligation (1,000) - Settlement of stock iswithholdi					
Provision for deferred income taxes 76 289 Foreign exchange loss (gain) 610 (16) Interest accretion 596 857 Loss on sale of assets - 172 Stock-based compensation expense 4,914 5,396 Change in contingent consideration (3,090) (2,515) Adjustment of goodwill - 36 Changes in operating assets and liabilities, net of businesses acquired: - 36 Accounts receivable 1,493 (620) Inventory 122 (104) Other assets 6,693 (10,366) Net cash provided by operating activities (6,593) (10,366) Net cash provided by operating activities (2,588) (2,928) Capitalized software (9,179) (7,636) Cash paid for acquisition (net) - (12,582) Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: (11,767) (23,146) Preferred stock dividends paid (15,314) (14,437) Se					
Foreign exchange loss (gain)					
Loss on sale of assets					
Loss on sale of asserts					
Change in contingent consideration (3,090) (2,515) Adjustment of goodwill 3 3 Changes in operating assets and liabilities, net of businesses acquired: 1,493 (620) Accounts receivable 1,493 (620) Contract asset 326 (620) Inventory 122 (104) Other assets (6,593) (10,366) Net cash provided by operating activities 21,151 13,334 INVESTING ACTIVITIES: 8 (2,928) Purchases of property and equipment (2,588) (2,928) Capitalized software (9,179) (7,636) Cash paid for acquisition (net) 1,1767) (23,146) Fundament of contingent obligation (net) (11,767) (23,146) Financing ACTIVITIES: 1 (15,314) (14,437) Settlement of contingent obligation (10,000) - Settlement of contingent obligation (10,000) - Settlement of contingent obligation on stock issued to employees (1,197) (2,123) Repayment of inex withholding obligations on	Loss on sale of assets		_		
Change in contingent consideration (3,090) (2,515) Adjustment of goodwill 3 3 Changes in operating assets and liabilities, net of businesses acquired: 1,493 (620) Accounts receivable 1,493 (620) Contract asset 326 (620) Inventory 122 (104) Other assets (6,593) (10,366) Net cash provided by operating activities 21,151 13,334 INVESTING ACTIVITIES: 8 (2,928) Purchases of property and equipment (2,588) (2,928) Capitalized software (9,179) (7,636) Cash paid for acquisition (net) 1,1767) (23,146) Fundament of contingent obligation (net) (11,767) (23,146) Financing ACTIVITIES: 1 (15,314) (14,437) Settlement of contingent obligation (10,000) - Settlement of contingent obligation (10,000) - Settlement of contingent obligation on stock issued to employees (1,197) (2,123) Repayment of inex withholding obligations on	Stock-based compensation expense		4,914		5,396
Adjustment of goodwill 36 Changes in operating assets and liabilities, net of businesses acquired: 1,493 (620) Contract asset 3.26 (620) Inventory 122 (104) Other assets 619 921 Accounts payable and other liabilities (6,593) (10,366) Net cash provided by operating activities 11,313 INVESTING ACTIVITIES: **** **** Purchases of property and equipment (2,588) (2,928) Capitalized software (9,179) (7,636) Cash paid for acquisition (net) - (12,582) Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: *** ** *** *** ***<			(3,090)		
Changes in operating assets and liabilities, net of businesses acquired: 1,493 (620) Accounts receivable 326 (620) Contract asset 326 (620) Inventory 122 (104) Other assets 619 921 Accounts payable and other liabilities (6,593) (10,366) Net cash provided by operating activities 21,151 13,334 INVESTING ACTIVITIES: Turchases of property and equipment (2,588) (2,928) Capitalized software (9,179) (7,636) (23,168) Cash paid for acquisition (net) - (12,582) (2,988) Net cash used in investing activities - (12,582) (2,988) Net cash used in investing activities - (12,582) (2,168) (2,288) Net cash used in investing activities - (11,677) (23,146) (23,146) FINANCING ACTIVITIES: Preferred stock dividends paid (15,314) (14,437) (31,600) (31,600) (31,600) (31,600) (4,162) (21,231)			-		
Accounts receivable 1,493 (620) Contract asset 36 (620) Inventory 122 (104) Other assets 619 921 Accounts payable and other liabilities (6,593) (10,366) Net cash provided by operating activities 21,151 13,334 INVESTING ACTIVITIES: 21,151 13,334 Purchases of property and equipment (2,588) (2,928) Capitalized software (9,179) (7,636) Cash paid for acquisition (net) - (12,582) Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: *** *** Preferred stock dividends paid (15,314) (14,437) Settlement of contingent obligation (10,000) - Settlement of tax withholding obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - 6,435 <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
Inventory			1,493		(620)
Other assets 619 921 Accounts payable and other liabilities (6,593) (10,366) Net cash provided by operating activities 21,151 33,34 INVESTING ACTIVITIES: Purchases of property and equipment (2,588) (2,928) Capitalized software (9,179) (7,636) Cash paid for acquisition (net) - (12,582) Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: Preferred stock dividends paid (15,314) (14,437) Settlement of contingent obligation (1,000) - Settlement of fax withholding obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - 6,435 Proceeds from issuance of Series B Preferred Stock, net of expenses 30,901 - Proceeds from line of credit (20,005) - Proceeds from line of credit (25,500) <t< td=""><td>Contract asset</td><td></td><td>326</td><td></td><td>(620)</td></t<>	Contract asset		326		(620)
Accounts payable and other liabilities (6,593) (10,366) Net cash provided by operating activities 21,151 13,334 INSESTING ACTIVITIES: 1 3,348 Purchases of property and equipment (2,588) (2,928) Capitalized software (9,179) (7,636) Cash paid for acquisition (net) - (12,582) Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: - - Preferred stock dividends paid (15,314) (14,437) Settlement of contingent obligation (1,000) - Settlement of stax withholding obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from issuance of Series B Preferred Stock, net of expenses 3,991 - Proceeds from issuance of Common stock, net of expenses 3,991 - Proceeds from lisuance of credit 25,500 26,000 Repayment of line of credit 25,500 26,000 <td>Inventory</td> <td></td> <td>122</td> <td></td> <td>(104)</td>	Inventory		122		(104)
Net cash provided by operating activities 21,151 13,334 INVESTING ACTIVITIES: 10,2588 (2,928) Purchases of property and equipment (2,588) (2,928) Capitalized software (9,179) (7,636) Cash paid for acquisition (net) - (12,582) Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: ************************************	Other assets		619		921
Purchases of property and equipment	Accounts payable and other liabilities		(6,593)		(10,366)
Purchases of property and equipment (2,588) (2,928) Capitalized software (9,179) (7,636) Cash paid for acquisition (net) - (12,582) Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: Preferred stock dividends paid (15,314) (14,437) Settlement of contingent obligation (1,000) - Settlement of tax withholding obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - 6,435 Proceeds from issuance of Series B Preferred Stock, net of expenses - 2,731 Redemption of Series A Preferred Stock (20,005) - Proceeds from line of credit (25,500) (50,000 Repayment of line of credit (25,500) (50,000 Repayment of line of credit (25,500) (51,000 Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANG	Net cash provided by operating activities		21,151		13,334
Capitalized software (9,179) (7,636) Cash paid for acquisition (net) - (12,582) Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: Preferred stock dividends paid (15,314) (14,437) Settlement of contingent obligations (1,000) - Settlement of tax withholding obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - 6,435 Proceeds from issuance of Series B Preferred Stock, net of expenses 30,901 - Proceeds from issuance of common stock, net of expenses 2 2,731 Redemption of Series A Preferred Stock (20,005) - Proceeds from line of credit (25,500) 26,000 Repayment of line of credit (25,500) (5190) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH	INVESTING ACTIVITIES:				
Capitalized software (9,179) (7,636) Cash paid for acquisition (net) - (12,582) Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: - (15,314) (14,437) Settlement of contingent obligation (1,000) - (1,213) Settlement of tax withholding obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - (6,435) Proceeds from issuance of Series B Preferred Stock, net of expenses - (2,731) Redemption of Series A Preferred Stock (20,005) - (2,731) Redemption of Series A Preferred Stock (20,005) - (2,731) Redemption of credit (25,500) (36,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,249 20,925 <td>Purchases of property and equipment</td> <td></td> <td>(2,588)</td> <td></td> <td>(2,928)</td>	Purchases of property and equipment		(2,588)		(2,928)
Cash paid for acquisition (net) - (12,582) Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: Preferred stock dividends paid (15,314) (14,437) Settlement of contingent obligation (1,000) - Settlement of tax withholding obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (10,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - 6,435 Proceeds from issuance of Series B Preferred Stock, net of expenses 30,901 - Proceeds from issuance of common stock, net of expenses 30,901 - Proceeds from line of credit (20,005) - Redemption of Series A Preferred Stock (20,005) - Proceeds from line of credit (25,500) (18,000) Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 1,959 (10,585)	Capitalized software				
Net cash used in investing activities (11,767) (23,146) FINANCING ACTIVITIES: Preferred stock dividends paid (15,314) (14,437) Settlement of contingent obligation (1,000) - Settlement of tax withholding obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - 6,435 Proceeds from issuance of Series B Preferred Stock, net of expenses 30,901 - Proceeds from issuance of common stock, net of expenses 30,901 - Proceeds from line of credit (20,005) - Repayment of line of credit (25,500) (26,000) Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925	Cash paid for acquisition (net)		-		
Proferred stock dividends paid (15,314) (14,437)			(11.767)		
Preferred stock dividends paid (15,314) (14,437) Settlement of contingent obligation (1,000) - Settlement of tax withholding obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - 6,435 Proceeds from issuance of Series B Preferred Stock, net of expenses 30,901 - Proceeds from issuance of common stock, net of expenses (20,005) - Proceeds from line of credit (20,005) - Proceeds from line of credit (25,500) (18,000) Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year 10,340 20,925 CASH AND RESTRICTED CAS					
Settlement of contingent obligation (1,000) - Settlement of tax withholding obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - 6,435 Proceeds from issuance of Series B Preferred Stock, net of expenses 30,901 - Proceeds from issuance of common stock, net of expenses - 2,731 Redemption of Series A Preferred Stock (20,005) - Proceeds from line of credit 25,500 26,000 Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year \$ 12,299 \$ 10,340 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition </td <td></td> <td></td> <td>(15.314)</td> <td></td> <td>(14.437)</td>			(15.314)		(14.437)
Settlement of tax withholding obligations on stock issued to employees (1,197) (2,123) Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - 6,435 Proceeds from issuance of Series B Preferred Stock, net of expenses 30,901 - Proceeds from issuance of common stock, net of expenses - 2,731 Redemption of Series A Preferred Stock (20,005) - Proceeds from line of credit (25,500) 26,000 Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year \$ 12,299 \$ 10,340 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition \$ - \$ (4,000) Contingent consideration at fai					-
Repayments of notes payable (1,003) (1,045) Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - 6,435 Proceeds from issuance of Series B Preferred Stock, net of expenses 30,901 - Proceeds from issuance of common stock, net of expenses - 2,731 Redemption of Series A Preferred Stock (20,005) - Proceeds from line of credit 25,500 26,000 Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year \$ 12,299 10,340 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition \$ - \$ 4,000 Contingent consideration at fair value at acquisition date \$ - \$ 5,605 Dividends declared, not paid \$ 4,059					(2,123)
Financing and stock issuance costs (32) (80) Proceeds from exercise of warrants - 6,435 Proceeds from issuance of Series B Preferred Stock, net of expenses 30,901 - Proceeds from issuance of common stock, net of expenses - 2,731 Redemption of Series A Preferred Stock (20,005) - Proceeds from line of credit 25,500 26,000 Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year \$ 12,299 \$ 10,340 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition \$ - \$ (4,000) Contingent consideration at fair value at acquisition date \$ - \$ 5,605 Dividends declared, not paid \$ 4,059 \$ 3,856 Purchase of prepaid insurance with assumption of					
Proceeds from exercise of warrants - 6,435 Proceeds from issuance of Series B Preferred Stock, net of expenses 30,901 - Proceeds from issuance of common stock, net of expenses - 2,731 Redemption of Series A Preferred Stock (20,005) - Proceeds from line of credit 25,500 26,000 Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year \$ 12,299 \$ 10,340 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition \$ - \$ (4,000) Contingent consideration at fair value at acquisition date \$ - \$ 5,605 Dividends declared, not paid \$ 4,059 \$ 3,856 Purchase of prepaid insurance with assumption of note \$ 695 \$ 967 SUPPLEMENTAL INFORMATION - Cash paid during the year for: <td></td> <td></td> <td></td> <td></td> <td></td>					
Proceeds from issuance of common stock, net of expenses - 2,731 Redemption of Series A Preferred Stock (20,005) - Proceeds from line of credit 25,500 26,000 Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year \$ 12,299 \$ 10,340 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition \$ - \$ (4,000) Contingent consideration at fair value at acquisition date \$ - \$ 5,605 Dividends declared, not paid \$ 4,059 \$ 3,856 Purchase of prepaid insurance with assumption of note \$ 695 967 SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$ 153 \$ 282			-		6,435
Redemption of Series A Preferred Stock (20,005) - Proceeds from line of credit 25,500 26,000 Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year \$ 12,299 10,340 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition \$ - \$ (4,000) Contingent consideration at fair value at acquisition date \$ - \$ 5,605 Dividends declared, not paid \$ 4,059 \$ 3,856 Purchase of prepaid insurance with assumption of note \$ 695 \$ 967 SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$ 153 \$ 282	Proceeds from issuance of Series B Preferred Stock, net of expenses		30,901		-
Proceeds from line of credit 25,500 26,000 Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year \$ 12,299 \$ 10,340 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition \$ - \$ (4,000) Contingent consideration at fair value at acquisition date \$ - \$ 5,605 Dividends declared, not paid \$ 4,059 \$ 3,856 Purchase of prepaid insurance with assumption of note \$ 695 \$ 967 SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$ 153 \$ 282	Proceeds from issuance of common stock, net of expenses		-		2,731
Repayment of line of credit (25,500) (18,000) Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH 225 (254) NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 1,959 (10,585) CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year \$12,299 \$10,340 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition \$- \$(4,000) Contingent consideration at fair value at acquisition date \$- \$5,605 Dividends declared, not paid \$4,059 \$3,856 Purchase of prepaid insurance with assumption of note \$695 \$967 SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$153 \$282	Redemption of Series A Preferred Stock		(20,005)		-
Net cash used in financing activities (7,650) (519) EFFECT OF EXCHANGE RATE CHANGES ON CASH NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year \$ 12,299 \$ 10,340 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition \$ - \$ (4,000) Contingent consideration at fair value at acquisition date \$ - \$ 5,605 Dividends declared, not paid \$ 4,059 \$ 3,856 Purchase of prepaid insurance with assumption of note \$ 695 \$ 967 SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$ 153 \$ 282	Proceeds from line of credit		25,500		26,000
EFFECT OF EXCHANGE RATE CHANGES ON CASH NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH CASH AND RESTRICTED CASH - Beginning of the year CASH AND RESTRICTED CASH - End of the year SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition Contingent consideration at fair value at acquisition date Dividends declared, not paid Purchase of prepaid insurance with assumption of note SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes 1,25 (254) (254) (254) (254) (254) (254) (254) (10,585) (10,58	Repayment of line of credit		(25,500)		(18,000)
NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH CASH AND RESTRICTED CASH - Beginning of the year CASH AND RESTRICTED CASH - End of the year SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition Contingent consideration at fair value at acquisition date Dividends declared, not paid Purchase of prepaid insurance with assumption of note SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes 1,959 (10,585) (10,5	Net cash used in financing activities		(7,650)		(519)
NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH CASH AND RESTRICTED CASH - Beginning of the year CASH AND RESTRICTED CASH - End of the year SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition Contingent consideration at fair value at acquisition date Dividends declared, not paid Purchase of prepaid insurance with assumption of note SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes 1,959 (10,585) (10,5	EFFECT OF EXCHANGE RATE CHANGES ON CASH		225		(254)
CASH AND RESTRICTED CASH - Beginning of the year 10,340 20,925 CASH AND RESTRICTED CASH - End of the year \$ 12,299 \$ 10,340 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition \$ - \$ (4,000) Contingent consideration at fair value at acquisition date \$ - \$ 5,605 Dividends declared, not paid \$ 4,059 \$ 3,856 Purchase of prepaid insurance with assumption of note \$ 695 \$ 967 SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$ 153 \$ 282	NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH				
CASH AND RESTRICTED CASH - End of the year SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition Contingent consideration at fair value at acquisition date Dividends declared, not paid Purchase of prepaid insurance with assumption of note SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$ 12,299 \$ 10,340 \$ (4,000) \$ - \$ (4,000) \$ 5,605 \$ 3,856 \$ 967 \$ 282					
SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: Preferred stock cancelled in connection with an acquisition \$ - \$ (4,000)\$ Contingent consideration at fair value at acquisition date \$ - \$ 5,605\$ Dividends declared, not paid \$ 4,059 \$ 3,856\$ Purchase of prepaid insurance with assumption of note \$ 695 \$ 967\$ SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$ 153 \$ 282\$		\$		\$	
Preferred stock cancelled in connection with an acquisition Contingent consideration at fair value at acquisition date Dividends declared, not paid Purchase of prepaid insurance with assumption of note SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$ 153 \$ 282	-	<u> </u>	12,200	<u> </u>	10,510
Contingent consideration at fair value at acquisition date \$\ -\ \\$ 5,605 Dividends declared, not paid \$\ \\$ 4,059 \$\ \\$ 3,856 Purchase of prepaid insurance with assumption of note \$\ \\$ 695 \$\ \\$ 967 SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$\ \\$ 153 \$\ \\$ 282		\$		\$	(4,000)
Dividends declared, not paid \$ 4,059 \$ 3,856 Purchase of prepaid insurance with assumption of note \$ 695 \$ 967 SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$ 153 \$ 282	-				
Purchase of prepaid insurance with assumption of note \$ 695 \$ 967 SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$ 153 \$ 282			4.050		
SUPPLEMENTAL INFORMATION - Cash paid during the year for: Income taxes \$ 153 \$ 282	_		· ·		
Income taxes <u>\$ 153</u> <u>\$ 282</u>		\$	695	\$	967
	• • •				
Interest <u>\$ 162</u> <u>\$ 103</u>	Income taxes	\$	153		
	Interest	\$	162	\$	103

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

TO COMPARABLE GAAP MEASURES (UNAUDITED)

The following is a reconciliation of the non-GAAP financial measures used by us to describe our financial results determined in accordance with accounting principles generally accepted in the United States of America ("GAAP"). An explanation of these measures is also included below under the heading "Explanation of Non-GAAP Financial Measures."

While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of our business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP.

Adjusted EBITDA to GAAP Net Income

Set forth below is a reconciliation of adjusted EBITDA to our GAAP net income.

	Three Months End	ed December 31,	Year Ended D	December 31,	
	2022	<u>2021</u>	2022	2021	
		(\$ in the	ousands)		
Net revenue	\$ 32,534	\$ 37,462	\$ 138,826	\$ 139,599	
GAAP net income	499	3,522	5,432	2,836	
Provision for income taxes	33	177	177	157	
Net interest expense	83	176	364	440	
Foreign exchange loss / other expense	353	73	712	241	
Stock-based compensation expense	1,515	1,390	4,914	5,396	
Depreciation and amortization	3,039	2,689	11,725	12,195	
Transaction and integration costs	152	246	876	1,364	
Net loss on lease termination, impairment and unoccupied lease charges	210	340	1,138	2,005	
Change in contingent consideration	(200)	(2,515)	(3,090)	(2,515)	
Adjusted EBITDA	\$ 5,684	\$ 6,098	\$ 22,248	\$ 22,119	

Non-GAAP Adjusted Operating Income to GAAP Operating Income

Set forth below is a reconciliation of our non-GAAP adjusted operating income and non-GAAP adjusted operating margin to our GAAP operating income and GAAP operating margin.

	Three M	onths En	ded De	ecember 31,	Year Ended D	ecember 31,		
	20	<u>2022</u> <u>2021</u>			2022		2021	
Net revenue	\$	32,534	\$	37,462	\$ 138,826	\$	139,599	
GAAP net income		499		3,522	5,432		2,836	
Provision for income taxes		33		177	177		157	
Net interest expense		83		176	364		440	
Other expense - net		337		16	637		96	
GAAP operating income		952		3,891	6,610		3,529	
GAAP operating margin		2.9%		10.4%	4.8%		2.5%	
Stock-based compensation expense		1,515		1,390	4,914		5,396	
Amortization of purchased intangible assets		1,391		1,801	6,277		8,880	
Transaction and integration costs		152		246	876		1,364	
Net loss on lease termination, impairment and unoccupied lease charges		210		340	1,138		2,005	
Change in contingent consideration		(200)		(2,515)	 (3,090)		(2,515)	
Non-GAAP adjusted operating income	\$	4,020	\$	5,153	\$ 16,725	\$	18,659	
Non-GAAP adjusted operating margin		12.4%		13.8%	12.0%		13.4%	

Non-GAAP Adjusted Net Income to GAAP Net Income

Set forth below is a reconciliation of our non-GAAP adjusted net income and non-GAAP adjusted net income per share to our GAAP net income and GAAP net loss per share.

	Three Months Ended December 31,					ıber 31,		
		2022		2021		2022		2021
			(\$ in	thousands, exc	ept fo	r per share amount	ts)	
GAAP net income	\$	499	\$	3,522	\$	5,432	\$	2,836
Foreign exchange loss / other expense		353		73		712		241
Stock-based compensation expense		1,515		1,390		4,914		5,396
Amortization of purchased intangible assets		1,391		1,801		6,277		8,880
Transaction and integration costs		152		246		876		1,364
Net loss on lease termination, impairment and unoccupied lease charges		210		340		1,138		2,005
Change in contingent consideration		(200)		(2,515)		(3,090)		(2,515)
Income tax expense related to goodwill		14		150		75		290
Non-GAAP adjusted net income	\$	3,934	\$	5,007	\$	16,334	\$	18,497
End-of-period shares		15,229,405		14,916,842		15,229,405		14,916,842
Non-GAAP adjusted net income per share	\$	0.25	\$	0.34	\$	1.07	\$	1.24

For purposes of determining non-GAAP adjusted net income per share, we used the number of common shares outstanding as of December 31, 2022 and 2021, respectively.

	Three Months Ended December 31,					Year Ended I)ece	mber 31,
		2022		2021		2022		2021
GAAP net loss attributable to common shareholders, per share	\$	(0.22)	\$	(0.01)	\$	(0.67)	\$	(0.77)
Impact of preferred stock dividend		0.25		0.25	_	1.03		0.96
Net income per end-of-period share		0.03		0.24		0.36		0.19
Foreign exchange loss / other expense		0.02		0.01		0.05		0.02
Stock-based compensation expense		0.10		0.09		0.32		0.36
Amortization of purchased intangible assets		0.09		0.12		0.41		0.60
Transaction and integration costs		0.01		0.02		0.06		0.09
Net loss on lease termination, impairment and unoccupied lease charges		0.01		0.02		0.07		0.13
Change in contingent consideration		(0.01)		(0.17)		(0.20)		(0.17)
Income tax expense related to goodwill		0.00	_	0.01		0.00		0.02
Non-GAAP adjusted earnings per share	\$	0.25	\$	0.34	\$	1.07	\$	1.24
End-of-period common shares		15,229,405		14,916,842		15,229,405		14,916,842
In-the-money warrants and outstanding unvested RSUs		598,245		684,528		598,245		684,528
Total fully diluted shares		15,827,650		15,601,370		15,827,650		15,601,370
Non-GAAP adjusted diluted earnings per share	\$	0.25	\$	0.32	\$	1.03	\$	1.19

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with accounting principles generally accepted in the United States of America, or GAAP. However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of CareCloud and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

Management uses adjusted EBITDA, adjusted operating income, adjusted operating margin, and non-GAAP adjusted net income to provide an understanding of aspects of operating results before the impact of investing and financing charges and income taxes. Adjusted EBITDA may be useful to an investor in evaluating our operating performance and liquidity because this measure excludes non-cash expenses as well as expenses pertaining to investing or financing transactions. Management defines "adjusted EBITDA" as the sum of GAAP net income (loss) before provision for (benefit from) income taxes, net interest expense, other (income) expense, stock-based compensation expense, depreciation and amortization, integration costs, transaction costs, impairment charges and changes in contingent consideration.

Management defines "non-GAAP adjusted operating income" as the sum of GAAP operating income (loss) before stock-based compensation expense, amortization of purchased intangible assets, integration costs, transaction costs, impairment charges and changes in contingent consideration, and "non-GAAP adjusted operating margin" as non-GAAP adjusted operating income divided by net revenue.

Management defines "non-GAAP adjusted net income" as the sum of GAAP net income (loss) before stock-based compensation expense, amortization of purchased intangible assets, other (income) expense, integration costs, transaction costs, impairment charges, changes in contingent consideration, any tax impact related to these preceding items and income tax expense related to goodwill, and "non-GAAP adjusted net income per share" as non-GAAP adjusted net income divided by common shares outstanding at the end of the period, including the shares which were issued but are subject to forfeiture and considered contingent consideration.

Management considers all of these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance.

In addition to items routinely excluded from non-GAAP EBITDA, management excludes or adjusts each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:

Foreign exchange / other expense. Other expense is excluded because foreign currency gains and losses and other non-operating expenses are expenditures that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expense is partially outside of our control. Foreign currency gains and losses are based on global market factors which are unrelated to our performance during the period in which the gains and losses are recorded.

Stock-based compensation expense. Stock-based compensation expense is excluded because this is primarily a non-cash expenditure that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expenditure is partially outside of our control because it is based on factors such as stock price, volatility, and interest rates, which may be unrelated to our performance during the period in which the expenses are incurred. Stock-based compensation expense includes cash-settled awards based on changes in the stock price.

Amortization of purchased intangible assets. Purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

Transaction costs. Transaction costs are upfront costs related to acquisitions and related transactions, such as brokerage fees, pre-acquisition accounting costs and legal fees, and other upfront costs related to specific transactions. Management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Integration costs. Integration costs are severance payments for certain employees relating to our acquisitions and exit costs related to terminating leases and other contractual agreements. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Net loss on lease termination, impairment and unoccupied lease charges. Net loss on lease termination represents the write-off of leasehold improvements and gains or losses as a result of an early lease termination. Impairment charges represent charges recorded for a leased facility no longer being used by the Company and a non-cancellable vendor contract where the services are no longer being used. Unoccupied lease charges represent the portion of lease and related costs for vacant space not being utilized by the Company. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Changes in contingent consideration. Contingent consideration represents the amount payable to the sellers of certain acquired businesses based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period, and changes arise from changes in the forecasted revenues of the acquired businesses.

Income tax expense related to goodwill. Income tax expense resulting from the amortization of goodwill related to our acquisitions represents a charge to record the tax effect resulting from amortizing goodwill over 15 years for tax purposes. Goodwill is not amortized for GAAP reporting. This expense is not anticipated to result in a cash payment.